Scarica l'app Stockscreener
9.48
3.95%
-0.39
Dopo l'orario di chiusura:
9.48
Precedente Chiudi:
$9.87
Aprire:
$9.5
Volume 24 ore:
706.90K
Relative Volume:
0.91
Capitalizzazione di mercato:
$483.97M
Reddito:
$85.21M
Utile/perdita netta:
$-140.11M
Rapporto P/E:
-3.77
EPS:
-2.5146
Flusso di cassa netto:
$-109.62M
1 W Prestazione:
-6.88%
1M Prestazione:
+1.61%
6M Prestazione:
+9.34%
1 anno Prestazione:
+189.02%
Intervallo 1D:
$9.375
$9.83
Intervallo di 1 settimana:
$8.45
$10.33
Portata 52W:
$2.235
$12.34
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
Nome
4 D Molecular Therapeutics Inc
Settore
Industria
Telefono
(510) 505-2680
Indirizzo
5858 HORTON STREET #455, EMERYVILLE
Compare FDMT vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
9.48 | 483.97M | 85.21M | -140.11M | -109.62M | -2.5146 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2025-11-07 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2025-01-13 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-11-21 | Iniziato | Morgan Stanley | Underweight |
| 2024-09-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2024-04-15 | Iniziato | Barclays | Overweight |
| 2024-02-07 | Ripresa | Goldman | Buy |
| 2023-10-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-18 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | Iniziato | Chardan Capital Markets | Buy |
| 2023-01-30 | Iniziato | BMO Capital Markets | Outperform |
| 2022-11-18 | Iniziato | H.C. Wainwright | Buy |
| 2022-11-15 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-08-12 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-06-22 | Iniziato | Jefferies | Buy |
| 2022-01-04 | Iniziato | SVB Leerink | Outperform |
| 2021-01-05 | Iniziato | BofA Securities | Buy |
| 2021-01-05 | Iniziato | Evercore ISI | Outperform |
| 2021-01-05 | Iniziato | Goldman | Neutral |
Mostra tutto
4 D Molecular Therapeutics Inc Borsa (FDMT) Ultime notizie
JPMorgan Chase & Co. Has $4.46 Million Stock Holdings in 4D Molecular Therapeutics, Inc. $FDMT - MarketBeat
4D Molecular Therapeutics, Inc. $FDMT Shares Sold by Assenagon Asset Management S.A. - MarketBeat
4D Molecular Therapeutics (NASDAQ:FDMT) Receives Buy Rating from Jefferies Financial Group - Defense World
4D Molecular Therapeutics Inc (FDMT) Stock Price Quote Today & Current Price Chart - Capital.com
4D Molecular Therapeutics Consolidates Financial Leadership Under New Role - TipRanks
FDMT SEC Filings4D Molecular Therapeutics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Trade 4D Molecular Therapeutics IncFDMT CFD - Capital.com
4D Molecular Therapeutics appoints Kristian Humer as Principal Accounting Officer - TradingView
4D Molecular Therapeutics (NASDAQ: FDMT) elevates CFO Kristian Humer to Principal Accounting Officer - Stock Titan
4D Molecular Therapeutics' (FDMT) "Buy" Rating Reaffirmed at Jefferies Financial Group - MarketBeat
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $32.71 Consensus Target Price from Analysts - Defense World
4D Molecular Therapeutics Inc : Jefferies Ass - Moomoo
CEO at 4D Molecular (NASDAQ: FDMT) awarded 750K stock options - Stock Titan
4D Molecular (NASDAQ: FDMT) awards 217,000 stock options to CLO - stocktitan.net
4D Molecular (NASDAQ: FDMT) awards 219,000 stock options to company officer - Stock Titan
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
4D Molecular Therapeutics (NASDAQ:FDMT) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Vanguard amendment shows 0 shares of 4D Molecular (NASDAQ: FDMT) - Stock Titan
4D Molecular Therapeutics (NASDAQ:FDMT) Trading 8.7% HigherHere's Why - MarketBeat
VP Gupta of 4d molecular sold $3357 in FDMT stock - Investing.com UK
4D Molecular (NASDAQ: FDMT) VP uses share sale to cover taxes - Stock Titan
Research Analysts Issue Forecasts for FDMT FY2030 Earnings - Defense World
HC Wainwright Reiterates “Buy” Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Scholar Rock Holding (SRRK) and Acrivon Therapeutics, Inc. (ACRV) - The Globe and Mail
4D Molecular Therapeutics (NASDAQ:FDMT) Raised to "Hold" at Wall Street Zen - MarketBeat
4D Molecular Therapeutics (NASDAQ:FDMT) Raised to “Hold” at Wall Street Zen - Defense World
4D Molecular Therapeutics (FDMT) Receives a Hold from Cantor Fitzgerald - The Globe and Mail
4D Molecular Therapeutics' (FDMT) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
4D Molecular Therapeutics’ (FDMT) Buy Rating Reaffirmed at Chardan Capital - Defense World
Reimbursement and Pricing Pressures Threaten Commercial Outlook for 4D Molecular Therapeutics’ Gene Therapies - TipRanks
4D Molecular Therapeutics (FDMT) Q4 Profit Challenges Longstanding Loss Narrative - simplywall.st
4D Molecular Therapeutics (NASDAQ:FDMT) Given New $35.00 Price Target at Royal Bank Of Canada - MarketBeat
4D Molecular Therapeutics (FDMT): RBC Capital Raises Price Targe - GuruFocus
Chardan Capital Reiterates "Buy" Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - MarketBeat
RBC Raises Price Target on 4D Molecular Therapeutics to $35 From $32, Keeps Outperform, Speculative Risk - marketscreener.com
4D Molecular Therapeutics (FDMT) Reports 2025 Financial Results, Advances 4D-150 Wet AMD Phase 3 Trials, and Extends Cash Runway Into 2028 - Minichart
4D Molecular Therapeutics, Inc. 2025 Annual Report: Innovative AAV Gene Therapy Pipeline for Retinal and Pulmonary Diseases - Minichart
4D Molecular Therapeutics, Inc. (FDMT) Q4 Results Surpass Forecasts for Earnings and Revenue - Bitget
4D Molecular Therapeutics, Inc. (FDMT) Q4 earnings and revenues beat estimates - MSN
4D Molecular Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates - Yahoo Finance
4D Molecular Therapeutics : 4DMT Corporate Presentation – March 2026 (dfceb5) - marketscreener.com
4D Molecular Therapeutics 10-K: $85.2M collaboration revenue; improved net loss $140.1M - TradingView
4D Molecular Therapeutics (NASDAQ:FDMT) Announces Quarterly Earnings Results, Beats Estimates By $0.96 EPS - MarketBeat
4D Molecular Therapeutics (FDMT) details retina and lung gene therapy pipeline in 10-K - Stock Titan
4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones - The Manila Times
4D Molecular Therapeutics (NASDAQ: FDMT) posts 2025 results, inks Otsuka deal, extends cash runway - Stock Titan
Biotech 4D Molecular Therapeutics lines up March investor conference talks - Stock Titan
4D Molecular Therapeutics Highlights 4D-150 Phase III Momentum, DME Plans, Cash Runway at Leerink Conference - MarketBeat
4D Molecular Therapeutics Maps Phase 3 4D-150 Timeline, DME Expansion in Barclays Conference Talk - MarketBeat
FDMT: 4D-150's rapid phase III progress and broad commercialization plans highlight strong market potential - TradingView
4 D Molecular Therapeutics Inc Azioni (FDMT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):